PDS Biotechnology Corp PDSB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.82
- Day Range
- $3.71–4.00
- 52-Week Range
- $2.59–10.27
- Bid/Ask
- $3.66 / $3.89
- Market Cap
- $136.81 Mil
- Volume/Avg
- 171 / 896,970
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 25
- Website
- https://www.pdsbiotech.com
Comparables
Valuation
Metric
|
PDSB
|
CLDX
|
RCUS
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.72 | 3.27 | 2.57 |
Price/Sales | — | 352.32 | 9.93 |
Price/Cash Flow | — | — | — |
Price/Earnings
PDSB
CLDX
RCUS
Financial Strength
Metric
|
PDSB
|
CLDX
|
RCUS
|
---|---|---|---|
Quick Ratio | 4.15 | 13.69 | 4.35 |
Current Ratio | 4.33 | 13.87 | 4.52 |
Interest Coverage | −10.23 | — | −170.00 |
Quick Ratio
PDSB
CLDX
RCUS
Profitability
Metric
|
PDSB
|
CLDX
|
RCUS
|
---|---|---|---|
Return on Assets (Normalized) | −54.59% | −30.49% | −20.42% |
Return on Equity (Normalized) | −105.82% | −33.19% | −44.44% |
Return on Invested Capital (Normalized) | −59.98% | −32.85% | −49.53% |
Return on Assets
PDSB
CLDX
RCUS
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lzbwwctqpl | Mjfc | $547.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lkrjlnymy | Yjcvv | $105.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jqqfdtrlp | Bbthdvl | $104.0 Bil | |
MRNA
| Moderna Inc | Dzhrpfnyk | Gwksh | $46.8 Bil | |
ARGX
| argenx SE ADR | Dpfgjky | Jfbcg | $23.2 Bil | |
BNTX
| BioNTech SE ADR | Nwynmrc | Jtswv | $22.5 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mylwgvln | Pzycsxp | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xhchgtfl | Bqxtms | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yxngwpsdx | Hsmfz | $12.8 Bil | |
INCY
| Incyte Corp | Vgtbtrv | Hjdqn | $12.1 Bil |